Core Points - CoreWeave Inc. will participate in the Wells Fargo TMT Conference on November 18th, with CFO Nitin Agrawal presenting [1] - A live webcast and replay of the presentation will be available on CoreWeave's Investor Relations site [1] - CoreWeave is recognized as "The Essential Cloud for AI," providing technology and tools for innovators in the AI space [3] - The company was established in 2017 and went public on Nasdaq under the ticker CRWV in March 2025 [3] Company Information - CoreWeave serves leading AI labs, startups, and global enterprises, combining infrastructure performance with technical expertise [3] - The company emphasizes its role as a force multiplier in accelerating breakthroughs in AI [3] - CoreWeave's investor relations page and social media accounts are used for disclosing material non-public information [2]

CoreWeave Q3'25 Earnings Presentation November 10, 2025 1 2 Q3'25 at a Glance STRONG REVENUE TRAJECTORY Q1' 25 QoQ Revenue $1.4 billion ADJUSTED EBITDA3 ADJUSTED OPERATING INCOME3 61% Margin $838 million $217 million 16% Margin up 134% YoY STRONG REVENUE TRAJECTORY REVENUE BACKLOG1 $55.6 billion up 271% YoY REVENUE STRONG REVENUE TRAJECTORY CAPITAL EXPENDITURES 2 $1.9 billion $(41) million (3)% Margin ADJUSTED NET INCOME (LOSS) 3 Forward-Looking Statements This presentation contains "forward-looking stateme ...

Core View - CoreWeave reaffirms its commitment to acquiring Core Scientific, emphasizing the financial benefits and strategic rationale for Core Scientific stockholders [1][2][6] Acquisition Details - CoreWeave entered into a definitive agreement to acquire Core Scientific in an all-stock transaction on July 7, 2025, which is positioned as the best path forward for Core Scientific stockholders, providing immediate premium value and long-term growth potential [2][4] - The acquisition is expected to create synergies through vertical integration, operational efficiencies, and expanded industry expertise, enhancing long-term value creation for shareholders [2][4] Response to Misleading Claims - CoreWeave addresses misleading statements made by Two Seas Capital regarding the acquisition, asserting that their offer is final and will not be modified [3][4] - The company argues that Core Scientific's standalone value-creation plan is riskier compared to the proposed acquisition, which mitigates significant execution risks and capital expenditure challenges [4][6] - CoreWeave highlights that its partnership has already led to a ~150% increase in Core Scientific's stock price over the 13 months prior to the acquisition announcement, compared to ~25% for peers [4][5] Market Position and Future Outlook - CoreWeave is confident that no alternative buyer can match its scale and ability to unlock value from Core Scientific's assets, reinforcing the strategic importance of the acquisition [5][9] - The upcoming Special Meeting on October 30, 2025, will allow stockholders to vote on the transaction, with CoreWeave urging them to support the merger proposal [7][8]

Core Insights - VCI Global Limited reported a significant revenue increase of 37% year-over-year, reaching US$18.7 million for the first half of 2025, driven primarily by technology development and consultancy [3][5][6] - The company achieved a remarkable 434% growth in revenue from technology development, solutions, and consultancy, totaling US$9.3 million [4][6] - Gross profit margin remained strong at 80%, indicating the scalability of VCI Global's technology-driven model [5] Financial Performance - Revenue from business strategy consultancy decreased by 27.5% to US$8.1 million, reflecting a normalization after a record 2024 [4][6] - Interest income increased by 88% to US$1.3 million, driven by an expanded loan portfolio and client financing activities [6][7] - Net profit for the first half of 2025 was US$4.7 million, a 13% decrease from the previous year, primarily due to higher operating expenses [8][11] Cost Structure - Total cost of services rose significantly by 334% to US$3.7 million, reflecting increased investments in AI infrastructure [8][12] - Employee benefit expenses increased by 60% to US$2.6 million, attributed to a larger workforce and higher benefits [10] - IT expenses surged to US$3.3 million, a dramatic increase from US$8.9 thousand in the prior-year period, due to investments in technological capabilities [12] Cash Flow and Capital Allocation - Net cash generated from operating activities improved to US$969 thousand, compared to US$9.5 million used in the same period last year [14] - Net cash used in investing activities rose to US$45.5 million, primarily for investments in financial assets and AI infrastructure [15] - Net cash generated from financing activities increased to US$41.3 million, bolstered by proceeds from share issuances [16] Strategic Outlook - The company is set to launch new initiatives, including a GPU Lounge and Cloud platform, to create recurring revenue streams [2][22] - VCI Global aims to expand its presence in AI, fintech, and digital assets, positioning itself at the intersection of these high-growth sectors [2][20]

Financial Performance - Revenue reached $1.213 billion, a 207% year-over-year increase, driven by strong demand for the company's AI Cloud Platform[9, 14, 15] - Adjusted EBITDA was $753 million, a threefold increase compared to Q2'24, with a margin of 62%[9, 22] - Adjusted operating income was $200 million, up 134% year-over-year, representing a 16% margin[9, 17, 18] - Adjusted net loss was $(131) million, with a margin of (11)%[9, 11, 21] Capital Expenditure and Infrastructure - Capital expenditures totaled $2.9 billion, the highest in the company's history, reflecting continued investment in scaling the platform[10, 27, 30] - The company has 33 data centers with ~470MW active power and ~2.2GW contracted power[32] Revenue Backlog - Revenue backlog reached $30.1 billion, an 86% year-over-year increase, driven by strategic deals and contract expansions[9, 23, 24, 26] - The revenue backlog increased 2x year-to-date[26] - 40% of the revenue backlog is expected to be recognized within 24 months, 45% between 25-48 months, and 15% between 49-72 months[24]